Elicio Therapeutics

About:

Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer.

Website: https://elicio.com

Twitter/X: eliciotx

Top Investors: Angion, Gastro-Intestinal Research Foundation, EFung Capital, Trend Investment Group, Thynk Capital

Description:

Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enable precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses.

Total Funding Amount:

$254M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2011-01-01

Contact Email:

info(AT)vedantra.com

Founders:

Darrell Irvine, Satish Jindal

Number of Employees:

1-10

Last Funding Date:

2024-08-12

IPO Status:

Public

Industries:

© 2025 bioDAO.ai